Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CAPR Capricor Therapeutics	$10.65 +1.6%	$10.34	$3.52 ▼ $23.40	$486.46M	0.85	1.73 million shs	898,340 shs
REPH Recro Pharma		$1.73	$1.38 ▼ $3.79	$117.93M	1.08	126,298 shs	141,800 shs
TBPH Theravance Biopharma	$9.15 -1.4%	$9.16	$7.44 ▼ $10.90	$457.51M	-0.1	269,757 shs	156,274 shs
ZVRA Zevra Therapeutics	$8.33 -1.4%	$7.62	$4.20 ▼ $9.76	$455.48M	1.87	645,774 shs	457,938 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CAPR Capricor Therapeutics	+2.24%	-4.81%	-19.57%	-27.52%	+74.96%
REPH Recro Pharma	0.00%	0.00%	0.00%	0.00%	0.00%
TBPH Theravance Biopharma	-0.22%	-1.80%	-4.82%	+2.20%	+11.27%
ZVRA Zevra Therapeutics	-2.31%	-1.86%	+17.36%	+14.34%	+81.33%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CAPR Capricor Therapeutics	1.6352 of 5 stars	3.5	1.0	0.0	0.0	2.0	0.8	0.6
REPH Recro Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TBPH Theravance Biopharma	0.7399 of 5 stars	2.1	0.0	0.0	0.0	1.6	2.5	0.6
ZVRA Zevra Therapeutics	2.7939 of 5 stars	4.6	0.0	0.0	0.0	3.4	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CAPR Capricor Therapeutics	3.00	Buy	$35.50	233.33% Upside
REPH Recro Pharma	0.00	N/A	N/A	N/A
TBPH Theravance Biopharma	2.25	Hold	$11.33	23.86% Upside
ZVRA Zevra Therapeutics	3.11	Buy	$22.29	167.54% Upside

Current Analyst Ratings Breakdown

Latest REPH, ZVRA, CAPR, and TBPH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/20/2025	CAPR Capricor Therapeutics	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$31.00
5/14/2025	ZVRA Zevra Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
5/14/2025	CAPR Capricor Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$30.00 ➝ $30.00
5/14/2025	ZVRA Zevra Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$25.00 ➝ $25.00
3/20/2025	CAPR Capricor Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$30.00 ➝ $30.00
3/17/2025	CAPR Capricor Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$77.00 ➝ $77.00
3/13/2025	ZVRA Zevra Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$23.00 ➝ $25.00
3/13/2025	ZVRA Zevra Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$20.00 ➝ $22.00
3/13/2025	ZVRA Zevra Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
3/12/2025	ZVRA Zevra Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$18.00
3/12/2025	ZVRA Zevra Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform

(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CAPR Capricor Therapeutics	$17.36M	28.02	N/A	N/A	$0.73 per share	14.59
REPH Recro Pharma	$75.36M	0.00	N/A	N/A	$0.90 per share	0.00
TBPH Theravance Biopharma	$65.27M	7.01	N/A	N/A	$4.28 per share	2.14
ZVRA Zevra Therapeutics	$40.59M	11.22	N/A	N/A	$1.71 per share	4.87

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CAPR Capricor Therapeutics	-$22.29M	-$1.42	N/A	N/A	N/A	-146.86%	-112.95%	-57.00%	8/6/2025 (Estimated)
REPH Recro Pharma	-$11.37M	-$0.31	N/A	N/A	N/A	-15.15%	-56.66%	-11.14%	N/A
TBPH Theravance Biopharma	-$55.19M	-$1.18	N/A	26.14	N/A	-78.18%	-24.79%	-13.43%	8/4/2025 (Estimated)
ZVRA Zevra Therapeutics	-$46.05M	-$1.90	N/A	41.65	N/A	-342.63%	-159.54%	-51.50%	8/12/2025 (Estimated)

Latest REPH, ZVRA, CAPR, and TBPH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	CAPR Capricor Therapeutics	-$0.33	-$0.53	-$0.20	-$0.53	$3.16 million	$2.73 million
5/13/2025	Q1 2025	ZVRA Zevra Therapeutics	-$0.21	-$0.06	+$0.15	-$0.06	$16.96 million	$20.40 million
5/8/2025	Q1 2025	TBPH Theravance Biopharma	-$0.11	-$0.27	-$0.16	-$0.27	$28.08 million	$15.39 million
3/19/2025	Q4 2024	CAPR Capricor Therapeutics	-$0.31	-$0.16	+$0.15	-$0.16	$9.87 million	$11.13 million
3/11/2025	Q4 2024	ZVRA Zevra Therapeutics	-$0.39	-$0.67	-$0.28	-$0.67	$8.93 million	$12.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CAPR Capricor Therapeutics	N/A	N/A	N/A	N/A	N/A
REPH Recro Pharma	N/A	N/A	N/A	N/A	N/A
TBPH Theravance Biopharma	N/A	N/A	N/A	N/A	N/A
ZVRA Zevra Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CAPR Capricor Therapeutics	N/A	4.19	4.19
REPH Recro Pharma	2.27	3.24	2.74
TBPH Theravance Biopharma	N/A	4.97	4.97
ZVRA Zevra Therapeutics	0.84	2.88	2.88

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CAPR Capricor Therapeutics	21.68%
REPH Recro Pharma	62.34%
TBPH Theravance Biopharma	99.10%
ZVRA Zevra Therapeutics	35.03%

Insider Ownership

Company	Insider Ownership
CAPR Capricor Therapeutics	10.50%
REPH Recro Pharma	14.20%
TBPH Theravance Biopharma	6.90%
ZVRA Zevra Therapeutics	2.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CAPR Capricor Therapeutics	N/A	45.68 million	40.01 million	Optionable
REPH Recro Pharma	185	56.42 million	48.41 million	Optionable
TBPH Theravance Biopharma	359	50.00 million	45.78 million	Optionable
ZVRA Zevra Therapeutics	20	54.68 million	52.10 million	Optionable

REPH, ZVRA, CAPR, and TBPH Headlines

Recent News About These Companies

Citizens JMP Reiterates Buy Rating on Zevra Therapeutics (ZVRA), Keeps PT

May 27 at 1:28 PM | insidermonkey.com

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Consensus Rating of "Buy" by Analysts

May 27 at 1:16 AM | marketbeat.com

Northern Trust Corp Buys 81,252 Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

May 25 at 3:07 AM | marketbeat.com

Zevra Therapeutics (NASDAQ:ZVRA) Upgraded to Buy at Wall Street Zen

May 24, 2025 | marketbeat.com

Zevra Therapeutics (NASDAQ:ZVRA) Upgraded at Wall Street Zen

May 24, 2025 | americanbankingnews.com

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Shares Bought by Woodline Partners LP

May 23, 2025 | marketbeat.com

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) is Velan Capital Investment Management LP's 9th Largest Position

May 21, 2025 | marketbeat.com

All Three Leading Proxy Advisory Firms – ISS, Glass Lewis, and Egan-Jones – Recommend Zevra Stockholders Vote FOR the Company's Director Nominees

May 21, 2025 | globenewswire.com

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Stock Holdings Lowered by Stonepine Capital Management LLC

May 20, 2025 | marketbeat.com

Q2 EPS Forecast for Zevra Therapeutics Raised by Analyst

May 20, 2025 | marketbeat.com

Research Analysts Offer Predictions for ZVRA Q2 Earnings

May 19, 2025 | americanbankingnews.com

Roth Capital Lifts Earnings Estimates for Zevra Therapeutics

May 18, 2025 | marketbeat.com

Analysts Offer Insights on Healthcare Companies: Flora Growth (FLGC), Cardinal Health (CAH) and Zevra Therapeutics (ZVRA)

May 16, 2025 | theglobeandmail.com

With 49% stake, Zevra Therapeutics, Inc. (NASDAQ:ZVRA) seems to have captured institutional investors' interest

May 15, 2025 | finance.yahoo.com

Zevra Reports First Quarter 2025 Financial Results and Corporate Update

May 14, 2025 | taiwannews.com.tw

Zevra Therapeutics, Inc. (ZVRA) Q1 2025 Earnings Call Transcript

May 13, 2025 | seekingalpha.com

Zevra Therapeutics (ZVRA) Reports Q1 Loss, Tops Revenue Estimates

May 13, 2025 | zacks.com

Zevra Therapeutics, Inc. Q1 2025 Earnings Preview

May 12, 2025 | msn.com

Zevra Therapeutics (ZVRA) Expected to Announce Earnings on Wednesday

May 9, 2025 | marketbeat.com

Zevra Therapeutics Announces Details for Q1 2025 Financial Results Call

May 6, 2025 | globenewswire.com

Barclays PLC Increases Holdings in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

May 3, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

REPH, ZVRA, CAPR, and TBPH Company Descriptions

Capricor Therapeutics NASDAQ:CAPR

$10.65 +0.17 (+1.62%)

Closing price 04:00 PM Eastern

Extended Trading

$10.70 +0.05 (+0.52%)

As of 07:59 PM Eastern

Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.

Recro Pharma NASDAQ:REPH

Recro Pharma, Inc. is a pharmaceutical company, which engages in the contract development and manufacturing organization (CDMO). The firm offers integrated solutions for formulation, analytical services, regulatory support, manufacturing and packaging of both commercial and development stage oral solid dose drug products. The company was founded by Geraldine A. Henwood and Thomas F. Henwood on November 15, 2007 and is headquartered in Exton, PA.

Theravance Biopharma NASDAQ:TBPH

$9.15 -0.13 (-1.40%)

Closing price 04:00 PM Eastern

Extended Trading

$9.15 +0.00 (+0.05%)

As of 04:04 PM Eastern

Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs. Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY. For more information, please visit www.theravance.com.

Zevra Therapeutics NASDAQ:ZVRA

$8.33 -0.12 (-1.42%)

Closing price 04:00 PM Eastern

Extended Trading

$8.32 -0.01 (-0.06%)

As of 04:04 PM Eastern

Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time